Morgado-Palacin, Lucia http://orcid.org/0000-0002-9138-290X
Brown, Jessie A. http://orcid.org/0000-0003-2396-5393
Martinez, Thomas F. http://orcid.org/0000-0002-4011-8164
Garcia-Pedrero, Juana M. http://orcid.org/0000-0002-5891-9488
Forouhar, Farhad
Quinn, S. Aidan
Reglero, Clara
Vaughan, Joan
Heydary, Yasamin Hajy
Donaldson, Cynthia
Rodriguez-Perales, Sandra http://orcid.org/0000-0001-7221-3636
Allonca, Eva http://orcid.org/0000-0002-2532-5421
Granda-Diaz, Rocio
Fernandez, Agustin F.
Fraga, Mario F. http://orcid.org/0000-0001-8450-2603
Kim, Arianna L.
Santos-Juanes, Jorge
Owens, David M.
Rodrigo, Juan P.
Saghatelian, Alan http://orcid.org/0000-0002-0427-563X
Ferrando, Adolfo A. http://orcid.org/0000-0002-6212-8574
Funding for this research was provided by:
Leukemia and Lymphoma Society (5461-18)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (K99CA267168, K01 CA249038, R35 CA210065)
Damon Runyon Cancer Research Foundation (DRSG-31-19)
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
Article History
Received: 25 January 2022
Accepted: 13 February 2023
First Online: 10 March 2023
Competing interests
: A.S. founded Velia Therapeutics and TFM consults and owns shares in Velia Therapeutics. J.A.B. and A.A.F. are currently employed by Regeneron Pharmaceuticals. The remaining authors declare no competing interests.